000			03244nam a2200301 u 4500
001			4904
003			GrATPDL
005			20240201094045.0
008			890105s1989 gw a b 101 0 eng
020			_a3540505342
040			_aGrATPDL _dΕΘΝΙΚΗ ΣΧΟΛΗ ΔΗΜΟΣΙΑΣ ΥΓΕΙΑΣ-ΚΕΝΤΡΙΚΗ ΒΙΒΛΙΟΘΗΚΗ _cΠΑΝΕΠΙΣΤΗΜΙΟΥΠΟΛΗ ΑΘΗΝΩΝ
041	0		_aeng
082			_a615.19
245	0	4	_aThe perception and management of drug safety risks / _cedited by Bruno Horisberger, Rolf Dinkel.
260			_aBerlin, Heidelberg ; _aNew York : _bSpringer Berlin Heidelberg, _c1989.
300			_axxiii, 210 σ. : _bεικ., διαγρ., πιν. ; _c25 εκ.
490	0		_aHealth Systems Research ; _v1431-4002
500			_aΠεριέχει παράρτημα με τα Βιογραφικά των συγγραφέων, γλωσσαριο και πίνακες.
504			_aΒιβλιογραφία : σ.191-201.
505			_aOpening Address -- I: Society and the Benefit/Risk Relationship -- 1. Acceptable Risk in Society -- 2. A Broad Framework for Confronting Health Risks -- 3. Communicating the Risks and Benefits of Technology: The Case of Pharmaceuticals -- 4. Overview of the Drug Safety Issue and Ciba-Geigy’s Response: RAD-AR -- 5. Summary of Part I: Presentations and Discussions -- II: Benefit/Risk Analysis and Appraisal -- 6. Limitations of Available Sources of Data on Prescription Drug Safety -- 7. Strategies, Designs, Criteria, Tactics and Statistics to be Considered when Evaluating Scientific Evidence -- 8. Statistics in Drug Risk Research: The Background of Pharmacoepidemiology -- 9. Industry-Sponsored Risk Institutes -- 10. The Feldene Experience: A Case Study -- 11. Risk Perception of Prescription Drugs: Report on a Survey in Sweden -- 12. Risk Perception of Prescription Drugs: Report on Surveys in Japan -- 13. Scientific and Political Components of Regulatory Decision Making: General Considerations -- 14. Scientific and Political Components of Regulatory Decision Making: The United States Experience -- 15. Summary of Part II: Presentations and Discussions -- III: Current Challenges -- 16. Professional Drug Information: A Consumer Perspective -- 17. Going Patient, Going Public -- 18. Reporting Adverse Drug Reactions: The Media Approach -- 19. What Can Be Learned from Drug Safety Issues? -- 20. Summary of Part III: Presentations and Discussions -- IV: Responding to the Issues -- 21. Editor’s Note -- 22. Pharmacoepidemiology -- 23. Risk Perception Analysis -- 24. Communicating the Benefit/Risk Relationship -- 25. Risk Appraisal on an International Scale -- V: Outlook -- 26. The Wolfsberg Questions -- VI: Annex -- 27. Curriculum Vitae of Authors -- 28. Bibliography -- 29. Subject Index -- 30. A Handbook of International Data Sources for Drug Benefit/Risk Assessment.
650		0	_aHealth risk assessment. _94495
650		0	_aΕκτίμηση κινδύνου για την υγεία. _94496
650		0	_aΦαρμακολογία. _93270
650		0	_aPharmacology. _93269
700	1		_aHorisberger, Bruno. _eΕπιμελητής _95825
700	1		_aDinkel, Rolf. _eΕπιμελητής _95826
942			_2ddc _cBK _h615.19 PER
999			_c5372 _d5372